35results about How to "Enhanced lethality" patented technology

The invention relates to a method for in-vitro amplification of NK cells, and in particular relates to a method for massive in-vitro amplification of NK cells, wherein the method comprises the following steps of: a, inoculating a peripheral blood mononuclear cell in a CD3McAb and CD226McAb pre-coated culture bottle for coculture; b, adding 1L-2 and 1L-18, coculturing for 72hours to stimulate amplification of NK cells; c, transferring the NK cells, K562 cells after lethal treatment and a serum-free medium containing 1L-2 and 1L-18 in a cell culture bag for coculture; and d, collecting the NK cells. According to the method for in-vitro amplification of the NK cells, two antibodies CD3McAb and CD226McAb are simultaneously coated, so the cell factor synthesis and ADCC effect are promoted, and killing toxicity of the NK cells is remarkably improved; the activation and amplification on the NK cells are achieved just by the 1L-2 and 1L-18 cell factors, so the amplification multiple and cell toxicity of the NK cells are guaranteed, and the cost of cell culture is reduced.

A detoxicating synergistic Chinese medicine for radiotherapy or chemicotherapy is prepared from astragalus root, wolfberry fruit and ganoderma. Its advantage is high curative effect.

The invention belongs to the field of cell culture, and particularly relates to a cell culture method. The cell culture method comprises the following steps that 1, a peripheral blood mononuclear cell is separated; 2, the peripheral blood mononuclear cell separated in the first step is added into a plasma-containing activated culture medium to activate NK cells; 3, a proliferation culture medium is added into the peripheral blood mononuclear cell which is cultured for 10 days in the second step to promote proliferation of the NK cells. According to the cell culture method, the technical defect that the amplified cell volume is low when the NK cells are subjected to in vitro expansion can be effectively overcome.

The invention relates to a new human cell factor BSTM1-v2 and application thereof, in particular to a gene or a protein of a transcript VSTM1-v2 of VSTM1 or immune fragments of the gene and the protein, and application of the gene or protein of the VSTM1-v2 or immune fragments of the gene and the protein in promoting Th17 differentiation and the function of killing CD8+ lymphocytes, and in preparing medicinal compositions for preventing and/or treating immune related diseases. The invention also relates to an antagonist of the VSTM1-v2, such as a monoclonal antibody or a polyclonal antibody, which comprises a vector, a host cell or a composition of the VSTM1-v2, a reagent for detecting the VSTM1-v2 or immune fragments thereof, and application of the antagonist and the reagent.

The invention discloses a chimeric antigen receptor and an application thereof in preparation of a product for treatment of tumors. The chimeric antigen receptor sequentially comprises a lead peptide,an anti-LILRB4 single-chain antibody, a human CD8 hinge transmembrane region, a human 4-1BB intracellular region, a human CD3 zeta intracellular region, a self-cleaving peptide and human IFN full length. A new generation of CAR-T cell treatment product is designed and developed by using LILRB4 as an antigen target for the first time, and a gene-optimized human full-length interferon (IFN) fragment is added to the C terminal of the LILRB4-CAR. Compared with a CAR-T cell which only expresses the LILRB4-CAR, the CAR-T cell which expresses the LILRB4-CAR-IFN has higher tumor killing capacity, andthe safety and effectiveness of the CAR-T cell in tumor treatment are further improved.

The invention relates to a herpes simplex virus type 1, which is a virus strain with an accession number of CCTCC NO. V201810, and an attenuated strain or a progeny culture thereof. The invention alsorelates to a composition containing the herpes simplex virus and a host cell infected by the herpes simplex virus.

The invention belongs to the field of biomedicine and discloses application of DC-CIK cells in preparation of a medicine used for resisting HIV infection. Through a lot of experiments, the inventor discovers that when CIK cells impacted by HIV and DC cells are co-cultured, the CIK cells can obviously promote maturation of the DC cells. When the DC and CIK cells are combined for use, the DC and CIK cells have mutual promotion presentation and a function for killing cells infected by HIV. After 30 days of the DC-CIK cell infusion, the number of CD4T cells of a HIV infector is obviously increased, the killing function of NK (Natural Killer) and CIK cells is enhanced, and HIV viral load is obviously restrained. Thus, kill cells induced by co-cultured dendritic cells and cytokines can be applied to the preparation of the medicine used for resisting HIV infection.

The invention discloses a H3N2 subtype canine influenza virus mouse adaptive virulent strain and application thereof. The techniques of virus isolation, culture, infection of animals and the like areadopted, enhanced virulence and pathogenic lethal amino acid mutations and deletions are obtained through adaptation of mice, and the H3N2 subtype canine influenza virus mouse adaptive virulent strainis obtained; the adaptive strain can cause lethal infection in mice, and a powerful animal model is provided for evaluation and development of a vaccine, effectiveness evaluation of prevention and treatment drugs and the like, influenza virus infection and pathogenic and lethal mechanism research. In addition, due to the fact that the mouse adapts to the virulent strain, an HA gene is not mutated, the antigenicity is unchanged, and the strain can serve as an antigen for basic experimental research such as preparation and/or detection based on antibody levels. In conclusion, the adaptive virulent strain provides the powerful technical support for research and development of the H3N2 subtype canine influenza virus vaccine and research of screening, infection, virulence enhancing and other mechanisms of the high-efficiency prevention and/or treatment drugs.

The invention discloses a composition capable of enabling the skin to defend pigments, and application. The composition comprises 1-4% of glutathione, 1-3% of arbutin, 0.2-0.6% of vitamin C, 0.1-2% ofvitamin E, 0.05-0.1% of indomethacin, 0.01-0.05% of 9-carotene, 0.1-0.6% of green tea, 0.2-0.7% of fructus mume extract, 0.2-0.9% of cortex cinnamomi extract, 2-12% of glycyrrhizae radix oil, 1-6% ofsoluble extract and the balance of water. Since the glutathione and the arbutin are added, formation of melanin is inhibited and disturbed so as to reduce skin pigment deposition and remove colored patches and freckles, the vitamin C, the vitamin E, the fructus mume extract and the soluble extract are combined to increase oxidation resistance capacity, the composition is prevented from being oxidized, the composition is guaranteed to still own an effect of inhibiting the formation of the melanin in the sun, and the skin fully defends the pigments.

The invention belongs to the technical field of biomedicines and in particular relates to protein nanoparticles carrying an antitumor peptide and a preparation method and application of the protein nanoparticles. The preparation method comprises the following steps: according to gene sequences of a pET25b(+)-HSP16.5 expression vector, synthesizing a single stranded DNA (deoxyribonucleic acid) sequence corresponding to an apoptosis-promoting peptide, namely KLAK peptide, performing annealing treatment, performing HindIII and XhoI double-digestion on the product and the vector, performing gel recycling on the digestion product, connecting the KLAK sequence with the vector, transforming the connection product into a competence of DH5a escherichia coli, picking a monoclonal bacterial colony, performing overnight bacterium shaking, extracting a plasmid, and performing sequencing; and transforming a pET25b(+)-HSP-KLAK plasmid with correct sequencing into a competence of BL21 escherichia coli, amplifying culture, performing ultrasonic bacterium crushing so as to obtain a corresponding crude product, performing purification, and performing dialysis, concentration and freeze-drying, so as to obtain an HSP-KLAK protein. The heat shock protein nanoparticles carrying the antitumor peptide, which are provided by the invention, can be rapidly taken in by tumor cells, after being released inlysosome, a targeting mitochondrion plays a role of tumor killing, the protein of the medicine carrier self can be rapidly degraded by cells, and thus a good tumor treatment effect can be achieved.